Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Reata Pharma (RETA)

Reata Pharma (RETA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,011,516
  • Shares Outstanding, K 30,271
  • Annual Sales, $ 26,520 K
  • Annual Income, $ -290,170 K
  • 60-Month Beta 2.58
  • Price/Sales 223.98
  • Price/Cash Flow N/A
  • Price/Book 23.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.98
  • Number of Estimates 4
  • High Estimate -1.85
  • Low Estimate -2.06
  • Prior Year -0.98
  • Growth Rate Est. (year over year) -102.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
186.50 +6.48%
on 01/27/20
257.96 -23.02%
on 02/05/20
+5.10 (+2.64%)
since 01/24/20
3-Month
186.50 +6.48%
on 01/27/20
257.96 -23.02%
on 02/05/20
-0.46 (-0.23%)
since 11/26/19
52-Week
70.00 +183.70%
on 08/28/19
257.96 -23.02%
on 02/05/20
+106.60 (+115.88%)
since 02/26/19

Most Recent Stories

More News
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December...

RETA : 198.59 (+1.22%)
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Programs on February 19, 2020

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development...

RETA : 198.59 (+1.22%)
CNS Pharmaceuticals Announces Completion of GMP Manufacturing

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has completed the final...

RETA : 198.59 (+1.22%)
CNSP : 3.79 (-5.01%)
CNS Pharmaceuticals Filed Request with FDA for Pre-IND Meeting for Berubicin

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, filed a Pre-IND meeting request for Berubicin for IV...

RETA : 198.59 (+1.22%)
CNSP : 3.79 (-5.01%)
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of...

RETA : 198.59 (+1.22%)
Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering

Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its...

RETA : 198.59 (+1.22%)
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 2,000,000 shares of its Class A common...

RETA : 198.59 (+1.22%)
Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -5.60% and 5.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

RETA : 198.59 (+1.22%)
Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019, and...

RETA : 198.59 (+1.22%)
Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development...

RETA : 198.59 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RETA with:

Business Summary

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address...

See More

Key Turning Points

2nd Resistance Point 208.19
1st Resistance Point 203.39
Last Price 198.59
1st Support Level 194.53
2nd Support Level 190.48

See More

52-Week High 257.96
Last Price 198.59
Fibonacci 61.8% 186.16
Fibonacci 50% 163.98
Fibonacci 38.2% 141.80
52-Week Low 70.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar